Exopharm Ltd (ex1) Logo

Exopharm Ltd (EX1)

___:___ · Healthcare

EX1 Chart


EX1's Principal Activity is the investment in biopharmaceutical drug development.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -72.05%
vs ASX 200 (1yr) -75.30%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,625 of 2,413
Sector Rank 146 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies AC8 / AZV / LBT
EPS -$0.062
DPS $0.00
Book Value Per Share $0.12

Broker Consensus

EX1 is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Exopharm Limited (EX1) is a clinical-stage Australian exosome medicine company developing naive exosome products for regenerative medicine and engineered exosomes for new precision medicines. Exopharm owns a purification technology called Ligand-based Exosome Affinity Purification (LEAP).

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Melbourne VIC 3000
Website www.exopharm.com
Registry Automic Group
Auditor William Buck Audit (VIC) Pty Ltd
Date Listed 18 Dec 2018

Upcoming Calendar (Forecasted)

No calendar entries available.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr David James Franks Company Secretary Sep 2021
Dr Jennifer (Jenn) King Non-Executive Director Sep 2021

Dr Jennifer (Jenn) King

Non-Executive Director

Dr King has experience in Pharmaceuticals and Biotechnology, having been Director, New Product Marketing in Shire Human Genetic Therapies, Senior Director Business Development & Licensing of Shire Pharmaceuticals supporting the rare disease business unit. More recently Jenn served as the Senior Vice President, Business Development of Intellia Therapeutics Inc., a pioneering company focused on the development of CRISPR/Cas9 genome editing therapies for patients with severe diseases. She has been involved in the emergence of nucleic acid medicines (DNA and RNA) within both Pharma and Biotech. With a network in North America, Jenn currently works as an independent consultant to a select group of emerging international biotechnology companies. She also served as a member of the Exopharm's Advisory Panel.

Ms Elizabeth McGregor Non-Executive Director Jan 2021

Ms Elizabeth McGregor

Non-Executive Director

Ms Elizabeth M McGregor is a corporate governance professional and is Company Secretary for a number of ASX listed entities. She has experience in various industries including investment management, e-commerce and biotechnology. Elizabeth is a Fellow of the Governance Institute of Australia, a Member of the Australian Institute of Company Directors and a NSW Justice of the Peace.

Mr Jason Mark Watson Non-Executive Chairman,Non-Executive Director Aug 2018

Mr Jason Mark Watson

Non-Executive Chairman,Non-Executive Director

Mr Watson has board and advisory experience acting with small and medium-sized enterprises, research institutes and listed companies in the life sciences and other sectors. In particular, Mr Watson has assisted companies in developing, commercialising and transacting technologies through significant biotechnology licensing deals. Mr Watson is principal of Elementary Law, a legal practice based in Melbourne, Australia. His practice focuses on assisting clients achieve the best outcomes for their patents and innovations, including through corporate fundraising, protection strategies, licensing and commercialisation. In this capacity, Mr Watson has been recognised in the Intellectual Asset Magazine Patent 1000 independent list of The World's 1000 Leading Patent Professionals. Mr Watson has expertise in relation to complex transactions, including establishing multi-party engagements, research and consultancy contracts and negotiating and implementing clinical trial, licensing, assignment, manufacturing, shareholding and other commercial arrangements.

Dr Ian Edward Dixon Managing Director May 2013

Dr Ian Edward Dixon

Managing Director

Dr Dixon founded Exopharm in 2013 and is a co-inventor of the LEAP Technology owned by Exopharm. He brings to the Board skills and experience across all areas of the business including technological, entrepreneurial and financial. As Managing Director, Dr Dixon manages processes within Exopharm including strategy, intellectual property, drug development, recruitment and technology commercialisation and development. Dr Dixon is also a Non-Executive Director and founder of Nyrada Inc. (ASX:NYR), and a co-inventor of the Nyrada cardiovascular drug NYX-330. In 2011, Dr Dixon Co-Founded Cynata Inc, a company that is progressing the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX:CYP). During the last three years, Dr Dixon has served as a director of the following listed companies: Medigard Ltd (ASX:MGZ) and Noxopharm Ltd (ASX:NOX).

Dr Gregory Lichtfuss Chief Operating Officer N/A
Dr Christopher Baldwin Deputy CEO & Chief Commercial Officer N/A

Director Transactions

EX1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
02/09/21 Elizabeth McGregor Buy +30,000 $0.54 $16,200 On-market trade
01/09/21 Ian Dixon Buy +83,333 $0.535 $44,583 Conversion of securities
01/09/21 Ian Dixon Exercise 83,333 $0.535 $44,583 Conversion of securities
01/09/21 Jason Watson Buy +30,000 $0.535 $16,050 Conversion of securities
01/09/21 Jason Watson Exercise 30,000 $0.535 $16,050 Conversion of securities
22/12/20 Jason Watson Buy +60,000 $0.328 $19,650 Off-market trade
02/12/20 Ian Dixon Issued 200,000 $0.36 $72,000 Issue of securities
09/11/20 Jason Watson Issued 90,000 $0.36 $32,400 Issue of securities
09/11/20 Ian Dixon Issued 250,000 $0.36 $90,000 Issue of securities
13/09/19 Jason Watson Issued 100,000 $0.37 $37,000 Placement
19/08/19 Jason Watson Buy +40,000 $0.37 $14,800 Participation in share purchase plan
19/08/19 David Parker Buy +20,000 $0.37 $7,400 Participation in share purchase plan
19/08/19 Ian Dixon Buy +40,000 $0.37 $14,800 Participation in share purchase plan

Director Interests

The current holdings of EX1 directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Elizabeth McGregor 02/09/2021 30,000 N/A N/A N/A
Jennifer (Jenn) King 01/09/2021 0 N/A N/A N/A
Jason Watson 01/09/2021 N/A 380,000 N/A N/A
Ian Dixon 01/09/2021 N/A 28,258,627 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 6, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Altnia Holdings Pty Ltd (Dixon Family A/C) 28,175,294 17.93%
Kyriaco Barber Pty Ltd 10,611,100 6.75%
Kohen Enterprises Pty Ltd 2,002,000 1.27%
Mr Paul Joseph Cozzi 2,000,000 1.27%
Citicorp Nominees Pty Limited 1,648,230 1.05%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon <Mcmahon Super Fund A/C> 1,635,849 1.04%
Oldview Enterprises Pty Ltd <The Priestley A/C> 1,610,000 1.02%
Development Management & Constructions <The Three Sisters A/C> 1,545,350 0.98%
Mr Russell Neil Creagh 1,457,000 0.93%
Mr Peter Dallas Checkley & Ms Niomie Esther Varady <Checkley Family S/F A/C> 1,410,275 0.90%
Mr Norman Cipriano 1,312,500 0.84%
Zessham Pty Ltd <Zessham A/C> 1,300,000 0.83%
Dixson Trust Pty Limited 1,231,000 0.78%
Mr Anthony John Locantro 1,120,000 0.71%
Mr Andrew Fay 1,000,000 0.64%
Mrs Anna Felicia Belton 1,000,000 0.64%
Sentinel Investment Management Limited <Rhea Investment A/C> 1,000,000 0.64%
Mr John Gardner 925,000 0.59%
Christopher Baldwin 876,666 0.56%
Acns Capital Markets Pty Ltd 865,000 0.55%
Canary Capital Pty Ltd 800,000 0.51%
Dr Raoul Pope 757,506 0.48%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 219 669 398 974 229 2,489

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Altnia Holdings Pty Ltd 06/08/2021 28,175,294 8.05
Carl Charalambous 11/02/2022 13,786,272 8.77

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
11-02-22 Carl Charalambous 2,414,454 7.23 8.77
27-09-21 Carl Charalambous 2,717,906 6.21 7.23

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.495 30 June
2020 $0.25 30 June
2019 $0.41 28 June
EX1 Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.